Cervical cancer, primarily caused by human papilloma virus (HPV) subtypes 16 and 18, leads to significant mortality globally. Locally advanced cervical cancer, particularly with para-aortic lymph node (PALN) metastases, presents a poor prognosis with a 5-year survival rate of approximately 40%. The NRG Oncology GY017 trial aims to evaluate the efficacy of combining Anti PD-L1 (atezolizumab) with chemoradiotherapy in this high-risk group.
Immunotherapy, specifically immune checkpoint blockade, has shown promise in treating cervical cancer by overcoming tumor-induced immunosuppression. Radiation therapy is known to enhance the immune response by increasing tumor infiltrating lymphocytes (TIL) and altering the T cell repertoire. The trial hypothesizes that administering atezolizumab before and during chemoradiation will prime the immune system, potentially improving treatment outcomes.
The study design includes two treatment arms: Arm A receives atezolizumab before and during chemoradiation, while Arm B receives atezolizumab only during chemoradiation. The primary objective is to assess immune activation through T cell receptor beta (TCRB) clonal expansion in peripheral blood. Secondary objectives include evaluating the feasibility and toxicity of atezolizumab with chemoradiation and correlating immune changes with clinical outcomes.
This phase I trial is significant for its focus on translational endpoints, aiming to provide insights into the optimal sequencing of immunotherapy and radiation. It targets patients with the highest risk of recurrence, offering a novel approach to improve survival rates in locally advanced cervical cancer. The trial's outcomes could pave the way for future clinical trials and treatment protocols, emphasizing the importance of combining immunotherapy with traditional cancer therapies.
